Snapshot from Jul 31, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / OneSource-Formycon biosimilar...
Business strategic partnership

OneSource-Formycon biosimilar manufacturing partnership

Analysis based on 7 articles · First reported Jul 14, 2026 · Last updated Jul 14, 2026

Sentiment
10
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The partnership strengthens OneSource's position as a global CDMO and provides Formycon with reliable, scalable manufacturing capacity. The market reaction was mildly negative for OneSource's stock, possibly due to near-term investment costs, but the long-term strategic value is positive for both companies.

Pharmaceuticals Biotechnology
Event Summary

OneSource Specialty Pharma, a multi-modality specialty pharma CDMO, and Formycon AG, an independent biosimilar developer headquartered in Germany — Munich, announced a strategic manufacturing partnership for biosimilars. Under the partnership, OneSource will serve as a strategic manufacturing partner for Formycon, providing integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its biologics facility in India — Bengaluru, India. The collaboration combines Formycon's biosimilar development expertise with OneSource's end-to-end biologics manufacturing platform to support Formycon's global biosimilar pipeline. OneSource operates five manufacturing facilities approved by the US FDA and EMA. Formycon currently has three marketed biosimilars and four pipeline candidates. The partnership aligns with Formycon's FYB4Growth strategy and reinforces India's position as a global hub for biologics manufacturing. Shares of OneSource fell on the announcement, trading down about 1.6% on the NSE.

Key Actions
80 OneSource Specialty Pharma partnered with Formycon AG
70 OneSource Specialty Pharma will manufacture Formycon AG
Entities Involved
priv
OneSource Specialty Pharma
OneSource enters a strategic manufacturing partnership with Formycon, providing integrated DS/DP manufacturing from its India — Bengaluru facility, enhancing its global CDMO credentials.
Importance 100.0 Sentiment 10.0
stock
Formycon AG
Formycon adds OneSource to its manufacturing network, supporting its biosimilar pipeline and FYB4Growth strategy with cost-efficient, scalable supply.
Importance 100.0 Sentiment 10.0
per
Neeraj Sharma
As Managing Director & CEO of OneSource, he announced the partnership, highlighting India's role in biologics manufacturing.
Importance 30.0 Sentiment 0.0
per
Stefan Glombitza
As CEO of Formycon, he emphasized the partnership's alignment with the company's growth strategy and quality standards.
Importance 30.0 Sentiment 0.0
cnt
India
The partnership reinforces India's position as a global hub for biologics manufacturing, benefiting the country's pharmaceutical sector.
Importance 20.0 Sentiment 10.0
loc
India — Bengaluru
OneSource's biologics facility in India — Bengaluru will be the manufacturing site for the partnership, highlighting the city's role in biopharma.
Importance 10.0 Sentiment 5.0
govactor
United States — Food and Drug Administration
OneSource's facilities are approved by the US FDA, which is a prerequisite for manufacturing biosimilars for the US market.
Importance 10.0 Sentiment 0.0
govactor
European Union — European Medicines Agency
OneSource's facilities are approved by the EMA, enabling manufacturing for European markets.
Importance 10.0 Sentiment 0.0
loc
Germany — Munich
Germany — Munich is the headquarters of Formycon, but the event does not directly impact the city.
Importance 5.0 Sentiment 0.0
exch
Frankfurt Stock Exchange
Formycon is listed on the Frankfurt Stock Exchange; the partnership may influence its stock, but no immediate price impact reported.
Importance 5.0 Sentiment 0.0
exch
National Stock Exchange of India
OneSource's shares traded on the NSE fell about 1.6% on the announcement, reflecting a mildly negative market reaction.
Importance 5.0 Sentiment -5.0
Relationships
India related ↔ United States — Food and Drug Administration
United States — Food and Drug Administration related ↔ European Union — European Medicines Agency
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.